BASEL, Switzerland and LONDON and NEW YORK and DURHAM, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 VALOR ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The phase 3 study will evaluate brepocitinib’s efficacy ...
Roivant Sciences Ltd (NASDAQ:ROIV) and Priovant Therapeutics released results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis (DM). Dermatomyositis is a chronic autoimmune ...
VALOR is the largest interventional dermatomyositis study ever conducted. Double-blind placebo-controlled study enrolled 241 subjects randomized 1:1:1 to brepocitinib 30 mg, brepocitinib 15 mg, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results